Abstracts tagged "Rheumatoid Factor"

Abstract Number: 0488 • ACR Convergence 2024
Association of Anti-CarP Levels with Clinical Activity and Serological Profile in Rheumatoid Arthritis
Pablo Martínez Calabuig¹, Elena Grau García², Samuel Leal Rodriguez², Ernesto Tovar Sugrañes³, José Ivorra-Cortés⁴, Carmen Riesco Barcena³, Anderson Huaylla Quispe³, Laura Mas Sánchez⁵, Pablo Muñoz Martínez⁶, Daniel Ramos Castro³, Alba Torrat noves⁷, Iago Alcantara Alvarez⁸, Belén Villanueva Mañés⁸, Miguel Simeo Vinaixa⁸, Andrés Pérez Hurtado³ and Jose A Román-Ivorra⁹, ¹HOSPITAL GENERAL UNIVERSITARIO VALENCIA SPAIN, Ontinyent, Comunidad Valenciana, Spain, ²HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Valencia, Spain, ⁴Hospital Universitario La Fe, PALMA DE MALLORCA, Spain, ⁵Resident at Hospital Universitari i Politecnic La Fe, Valéncia, Spain, ⁶Hospital Universitario y Politècnico La Fe, Sagunto, Spain, ⁷Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Comunidad Valenciana, Spain, ⁸Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Hospital Universitari i Politècnic la Fe, Valencia, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease where the presence of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (antiCCP) has been associated to…
Abstract Number: 0498 • ACR Convergence 2024
ACPA Subtypes, RF Isotypes, and the Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease
Jacob Welch¹, Yangyuna Yang¹, Joshua Baker², Katherine Wysham³, Dana Ascherman⁴, Paul Monach⁵, Gail Kerr⁶, Andreas Reimold⁷, grant Cannon⁸, Gary Kunkel⁹, William Robinson¹⁰, Michael Duryee¹, Geoffrey Thiele¹, Ted Mikuls¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵VA Boston Healthcare System, Boston, MA, ⁶Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁷Dallas VA Medical Center, Dallas, TX, ⁸University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹⁰Stanford University, Palo Alto, CA
Background/Purpose: Interstitial lung disease (ILD) is among the most significant extra-articular manifestations of rheumatoid arthritis (RA), clinically affecting 8-15% of RA patients, and accounting for…
Abstract Number: 0511 • ACR Convergence 2024
Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial
Josef Smolen¹, Ted Mikuls², James Galloway³, Ulf Müller-Ladner⁴, Jeffrey Curtis⁵, Motomu Hashimoto⁶, Tsutomu Takeuchi⁷, Ernest Choy⁸, Yoshiya Tanaka⁹, Carlos Cara¹⁰, Bernard Lauwerys¹¹, Nicola Tilt¹², Baran Ufuktepe¹³ and Peter C. Taylor¹⁴, ¹Medical University of Vienna, Vienna, Austria, ²University of Nebraska Medical Center, Omaha, NE, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁴Justus-Liebig University Giessen, Bad Nauheim, Germany, ⁵University of Alabama at Birmingham, Hoover, AL, ⁶Osaka Metropolitan University, Osaka, Japan, ⁷Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁸Cardiff University School of Medicine, Cardiff, United Kingdom, ⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ¹⁰UCB Pharma, Madrid, Spain, ¹¹UCB Pharma, Brussels, Belgium, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Istanbul, Turkey, ¹⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: In pts with RA, high RF levels are associated with poor prognosis, higher disease activity, and decreased response to monoclonal antibodies targeting tumor necrosis…
Abstract Number: 0777 • ACR Convergence 2024
Rheumatoid Factor B Cell Clones Proliferate Predominantly as Atypical Memory B Cells in Reactive Cervical Lymph Node Follicles Compared to Extrafollicular Sites in Affected Salivary Glands of SjS Patients
Theodoros Ioannis Papadimitriou¹, Jing Jing Wang², Xuehui He³, Sidney van der Zade⁴, Massis Krekorian⁵, Prashant Singh⁶, Erik Dik⁵, Ger Pruijn⁵, Tom Gordon², Hans Koenen⁷, Martijn Huijnen⁸ and Rogier Thurlings¹, ¹Radboudumc, Department of Rheumatology, Nijmegen, Gelderland, Netherlands, ²Flinders University, Adeleide, Australia, ³Radboudumc, Nijmegen, Netherlands, ⁴Radboudumc, Amsterdam, Netherlands, ⁵Radboudumc, Nijmegen, Gelderland, Netherlands, ⁶Radboudumc, Department of Medical BioSciences, Nijmegen, Netherlands, ⁷Radboudumc, Department of Medical Immunology, Nijmegen, Gelderland, Netherlands, ⁸Radboudumc, Department of Medical BioSciences, Nijmegen, Gelderland, Netherlands
Background/Purpose: Sjögren’s syndrome (SjS) is a chronic inflammatory disorder, characterized by formation of autoantibodies. Over time rheumatoid factor (RF) clones can give rise to cryoglobulinemic…
Abstract Number: 1009 • ACR Convergence 2024
Immunogenicity of the Recombinant Zoster Vaccine in People with Rheumatoid Arthritis Using Abatacept
Kevin Winthrop¹, Jeremy Hawkins², Adriana Weinberg³, Sarah Siegel², Jessica Baxter³, Krystle Garth³, Joseph Huffstutter⁴, James Loveless⁵, Suzanne gharib⁶, Shanmugapriya (Priya) Reddy⁷, Jayashree Sinha⁸, Elvia Moreta⁹, David Ridley¹⁰, Ilhem Messaoudi¹¹ and Jeffrey Curtis¹², ¹School of Medicine, Oregon Health and Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR, ³University of Colorado, Aurora, CO, ⁴Arthritis Associates PLLC, Signal Mountain, TN, ⁵St Luke's Health System, Boise, ID, ⁶Charleston Area Medical Center, Charleston, MD, ⁷Southwest Florida Rheumatology, Riverview, FL, ⁸self employed, Clovis, NM, ⁹St. Paul Rheumatology, Eagan, ¹⁰St. Paul Rheumatology, Eagan, MN, ¹¹University of Kentucky, Lexington, ¹²University of Alabama at Birmingham, Hoover, AL
Background/Purpose: The adjuvanted recombinant glycoprotein E (gE) herpes zoster vaccine (RZV) received expanded approval for use in 2021 for adults receiving immunosuppression. Despite approval, little…
Abstract Number: 1388 • ACR Convergence 2024
CXC Chemokine Ligand 13 and Rheumatoid Factor as Pharmacodynamic Biomarkers for Abatacept Treatment in Patients with Rheumatoid Arthritis
Ting Wang¹, Ryan Stultz¹, Natalia Giltiay², Christian Lood¹ and Bobby Kwanghoon Han¹, ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, USA, Seattle, WA
Background/Purpose: Abatacept, a CTLA-4-Ig fusion protein, is widely used as a treatment for rheumatoid arthritis (RA). We conducted this study to identify novel predictive and…
Abstract Number: 1772 • ACR Convergence 2023
Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients
Adam Titi¹, Ryan Adyniec², Nat Murren¹ and Miriam Shelef¹, ¹University of Wisconsin, Madison, WI, ²University of Wisconsin-Madison, Madison, WI
Background/Purpose: Rheumatoid factors (RFs), antibodies canonically known to bind two conformational epitopes of IgG Fc, are a hallmark of rheumatoid arthritis (RA) but also can…
Abstract Number: 1915 • ACR Convergence 2023
Scleritis and Development of Autoimmune Disease: A Case Series
Tessalyn Morrison¹, Moriah Gottman², Marcia Friedman³ and Daniela Ghetie⁴, ¹University of Vermont, Burlington, VT, ²Oregon Health & Science University, Milwaukie, OR, ³Alpine Immune Sciences, Inc., Beaverton, OR, ⁴Oregon Health & Science University, Portland, OR
Background/Purpose: Scleritis involves inflammation of the sclera caused by trauma, infections, or autoimmune conditions. The purpose of our study was to understand the relationship between…
Abstract Number: 2141 • ACR Convergence 2023
Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR)
Kristina Lend¹, Jos W.R. Twisk², Nupur Kumar³, John Lampa⁴, Anna Rudin⁵, Merete Hetland⁶, Till Uhlig⁷, Dan Nordstrom⁸, Mikkel Østergaard⁹, Marte Schrumpf Heiberg¹⁰, Espen A Haavardsholm¹⁰, Bjorn Gudbjornsson¹¹, Tuulikki Sokka-Isler¹², Gerdur Maria Grondal¹³, Kim Hørslev-Petersen¹⁴, Michael Nurmohamed², Ronald van Vollenhoven² and Johan Frostegård³, ¹Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden, ⁴Stockholm County, Hãsselby, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁷Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁸Helsinki University Hospital, Helsinki, Finland, ⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ¹⁰Diakonhjemmet Hospital, Oslo, Norway, ¹¹Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ¹²Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹³Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ¹⁴University of Southern Denmark, Odense, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with an elevated risk for developing atherosclerotic cardiovascular disease (CVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key…
Abstract Number: 2148 • ACR Convergence 2023
Do High RF Titers Impact Response to TNF Inhibitors? Comparison of Certolizumab Pegol and Adalimumab in Patients with RA and High Titers of RF: A Post Hoc Analysis of a Phase 4 Trial
Josef S Smolen¹, Peter C. Taylor², Yoshiya Tanaka³, Carlos Cara⁴, Bernard Lauwerys⁵, Ricardo Xavier⁶, Jeffrey R Curtis⁷, Ted R Mikuls⁸ and Michael Weinblatt⁹, ¹Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴UCB Pharma, Madrid, Spain, ⁵UCB Pharma, Brussels, Belgium, ⁶Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ⁸Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁹Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: In patients with RA, high RF titers are considered a poor prognostic factor and are associated with higher disease activity, risk of radiographic progression,…
Abstract Number: 2183 • ACR Convergence 2023
Evolution of Lymphoma Predictors in Primary Sjogren’s Syndrome by Data Driven Analysis in Harmonized Patients
Andreas Goules¹, Loukas Chatzis², Vasileios pezoulas³, Francesco Ferro⁴, Valeria Manfrè⁵, Dimitrios Fotiadis³, Luca Quartuccio Quartuccio⁶, Chiara Baldini⁷, Salvatore De Vita⁵ and Athanasios Tzioufas¹, ¹Dept. of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, ²Dept. of Pathophysiology, School of Medicine, University of Athens, Cholargos Athens, Greece, ³Unit of Medical Technology and Intelligent Information Systems, Dept. of Materials Science and Engineering, University of Ioannina, Ioannina, Greece, ⁴Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁵Clinic of Rheumatology, Dept. of Medical and Biological Sciences, Udine University, Udine, Italy, ⁶Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, ⁷University of Pisa, Pisa, Italy
Background/Purpose: Lymphoma is the most serious complication of primary Sjogren'ssyndrome (pSS), occurring as a late sequel during disease course. So far, lymphomapredictors have been identified…
Abstract Number: 0205 • ACR Convergence 2023
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy
Jamie Chieh Lo¹, Ying-Nan Tsai², Cheng-Hao Tseng³, Yao-Chun Hsu⁴ and Song-Chou Hsieh⁵, ¹School of Medicine, I-Shou University, Kaohsiung, Taiwan, ²Department of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ³Division of Gastroenterology and Hepatology, E-Da Cancer Hospital, Kaohsiung, Taiwan, ⁴I-Shou University School of Medicine, E-Da Hospital Center of Liver Diseases, Kaohsiung, Taiwan, ⁵National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Chronic hepatitis C virus (HCV) infection is associated with autoimmune extrahepatic manifestations including increased production of autoantibodies such as rheumatoid factor (RF). Prior to…
Abstract Number: 0416 • ACR Convergence 2023
Association Between Sleep Disorders and Rheumatoid Arthritis: A Population-based Cohort Study
Rakesh Kumar¹, Edward Lovering¹, Chanakya Kodishala², Sara Achenbach³, Diego Carvalho¹, Cynthia Crowson¹, John Davis¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester Minnesota, Rochester, MN, ³Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Some sleep disorders (SD) are more prevalent in patients with chronic inflammatory diseases, such as Rheumatoid Arthritis (RA). However, most of the research has…
Abstract Number: 0980 • ACR Convergence 2023
Temporal Trends in Incidence Rates of Seropositive and Seronegative Rheumatoid Arthritis: A Danish Nationwide Population-based Study
Bolette Soussi¹, René Cordtz², Kirsten Duch², Salome Kristensen³, Asta Linauskas⁴, Christian Bork⁵, Erik Schmidt⁶ and Lene Dreyer³, ¹Center of Rheumatic Research Aalborg, Department of Rheumatology, and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark, ²Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ³Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁴Department of Rheumatology, North Denmark Region Hospital, and Department of Clinical Medicine, Aalborg University, Hjørring, Denmark, ⁵Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark, ⁶Department of Medicine and Cardiology, Viborg Regional Hospital, and Department of Clinical Medicine, Aalborg University, Viborg, Aalborg, Denmark
Background/Purpose: With growing availability of autoantibody testing and autoantibodies gaining more weight in the 2010 ACR/EULAR classification criteria of rheumatoid arthritis (RA), an increasing incidence…
Abstract Number: 1046 • ACR Convergence 2023
The Level of RF or Anti-CCP Antibody Affect Ultrasound Synovial Findings in Patients with Rheumatoid Arthritis?
Tadashi Okano¹, Kenji Mamoto¹, Yutaro Yamada¹, Shohei Anno², Yuka Domae¹, Shingo Washida¹, Asami Yagami¹, Yuko Yoshida¹, Tatsuya Koike³ and Hiroaki Nakamura¹, ¹Osaka Metropolitan University, Osaka, Japan, ²Yodogawa Christian Hospital, Osaka, Japan, ³Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan
Background/Purpose: Positive for auto-antibodies such as rheumatoid factor (RF) and anti-citrullinated peptide antibodies (CCP) or having high autoantibody titers is associated with the progression of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].